论文部分内容阅读
目的观察多西他赛联合表柔比星(TE方案)密集新辅助化疗治疗局部晚期乳腺癌(locally advanced breast cancer,LABC)的疗效和毒副作用。方法收集济宁市第一人民医院乳甲外科2008-01-01-2012-12-31收治的39例未经治疗的LABC患者接受TE方案密集新辅助化疗。TE方案:多西他赛75 mg/m2,持续1h静脉滴入,d1;表柔比星75mg/m2,静脉滴入,d1。14d为1个周期,共2~4个周期。患者治疗前均经组织穿刺活检明确诊断。结果 TE方案密集新辅助化疗在LABC的治疗中总有效率为74.4%,其中完全缓解6例(15.4%),部分缓解23例(59.0%)。患者3年无病生存率和总生存率分别为84.1%和96.7%。所有患者均有不同程度的白细胞下降及脱发,其次为恶心、呕吐、肝功能损害及腹泻,无化疗相关性死亡。结论 TE方案密集新辅助化疗在取得理想的治疗效果的同时缩短了治疗周期,有利于早日手术,且毒副作用可耐受。
Objective To observe the efficacy and side effects of docetaxel combined with epirubicin (TE regimen) intensive neoadjuvant chemotherapy in the treatment of locally advanced breast cancer (LABC). Methods 39 cases of untreated patients with LABC underwent TE-intensive neoadjuvant chemotherapy in the First Affiliated Hospital of Jining. TE program: docetaxel 75 mg / m2, continuous 1h intravenous infusion, d1; epirubicin 75mg / m2, intravenous infusion, d1.14d for a period of 2 to 4 cycles. Patients before treatment by biopsy needle biopsy diagnosis. Results The total effective rate of TE regimen neoadjuvant chemotherapy in the treatment of LABC was 74.4%, of which 6 cases (15.4%) were completely relieved and 23 cases (59.0%) partially relieved. Three-year disease-free survival and overall survival were 84.1% and 96.7%, respectively. All patients had different degrees of leukopenia and hair loss, followed by nausea and vomiting, liver damage and diarrhea, no chemotherapy-related deaths. CONCLUSION: TE-intensive neoadjuvant chemotherapy can shorten the treatment cycle while achieving the desired therapeutic effect, which is beneficial to early operation and tolerable side effects.